UAE says Sinopharm vaccine has 86pc efficacy against Covid-19

Published December 9, 2020
A woman holds vials labelled "Covid-19 Coronavirus Vaccine" over dry ice in this illustration taken on Dec 5. — Reuters/File
A woman holds vials labelled "Covid-19 Coronavirus Vaccine" over dry ice in this illustration taken on Dec 5. — Reuters/File

An experimental coronavirus vaccine developed by China National Pharmaceutical Group (Sinopharm) has 86 per cent efficacy, the health ministry of the United Arab Emirates said on Wednesday, citing an interim analysis of late-stage clinical trials.

While the positive data comes soon after last month’s upbeat results from Western rivals, such as Pfizer Inc, Moderna, AstraZeneca Plc and from Russia, neither the UAE nor Sinopharm have released detailed data from the pivotal study.

In July, the Gulf Arab state started Phase III clinical trials of the vaccine, developed by Beijing Institute of Biological Product, a unit of Sinopharm’s China National Biotec Group (CNBG).

In September, it authorised emergency use of the vaccine for certain groups, the first such international clearance for a vaccine developed in China.

The analysis also shows “99pc seroconversion rate of neutralizing antibody and 100pc effectiveness in preventing moderate and severe cases of the disease”, the ministry said in a statement carried by the state news agency.

“The analysis shows no serious safety concerns,” it said.

It also said it had officially registered the vaccine, without elaborating, and that 31,000 volunteers across 125 nationalities participated in the UAE trial.

It did not say what, if any, side effects it identified, how many participants have become ill or how many volunteers were given the vaccine or a placebo.

CNBG could not be immediately reached for comment.

The vaccine, which uses an inactivated virus unable to replicate human cells to trigger immune responses, requires two doses, past trial data has showed.

The UAE trial is a partnership between CNBG, Abu Dhabi-based artificial intelligence company Group 42 (G42) and the Abu Dhabi Department of Health.

Sinopharm and G42 have also expanded the trial to Egypt, Jordan and Bahrain.

Abu Dhabi, the UAE’s capital, this week said it was seeking volunteers to take part in clinical trials of Russia’s Covid-19 vaccine, known as Sputnik V.

The UAE, with a population of around nine million, has recorded 178,837 infections and 596 deaths from the disease.

The vaccine is among the three most advanced candidates from China in terms of development and has been used to vaccinate around one million people in the country under its emergency use programme.

Opinion

Israeli flashpoint
Updated 12 May 2021

Israeli flashpoint

There are persistent reports from the US suggesting that the mood over unquestioning backing for Israel is shifting.
Blaming envoys for the mess
Updated 12 May 2021

Blaming envoys for the mess

The prime minister appeared to be using his container approach in the realm of foreign policy.
No entry, no Eid
12 May 2021

No entry, no Eid

On this Eid, amid this mess, many chairs at muted celebratory meals will remain empty.
Election night confusion
Updated 11 May 2021

Election night confusion

Poll manipulation in Pakistan occurs in the run-up to elections and on election day itself.

Editorial

PM’s Saudi visit
Updated 12 May 2021

PM’s Saudi visit

It is very important that Pakistan take no step, or agree to any demand, that can have an adverse effect on national sovereignty.
12 May 2021

A new intifada?

THE situation in the occupied territories over the past few days has been incendiary, with tensions boiling over as...
Updated 12 May 2021

SOP violations

ON Monday, Sindh Police officials were given a well-deserved slap on the wrist by a judicial magistrate in Karachi...
11 May 2021

Kabul massacre

AFGHANISTAN is a land that has seen plenty of massacres during decades of unrest. However, despite this almost...
Divisive move
Updated 11 May 2021

Divisive move

The whole point of these reforms is to ensure that all major political stakeholders are on board, and that there is a consensus.
11 May 2021

Bank loan concerns

THE combined gross non-performing loan portfolio of the country’s banks and DFIs increased marginally by 2.6pc or...